Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $167
Benzinga Newsdesk 8 hours ago
Analyst RatingsNewsPrice Target
Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and raises the price target from $144 to $167.
Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and raises the price target from $144 to $167.